TherapeuticsMD
TXMD
87 hedge funds and large institutions have $384M invested in TherapeuticsMD in 2014 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 17 closing their positions.
2,382% more call options, than puts
Call options by funds: $273K | Put options by funds: $11K
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
23% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 26
5% more funds holding
Funds holding: 83 → 87 (+4)
0.08% less ownership
Funds ownership: 1.27% → 1.19% (-0.08%)
34% less capital invested
Capital invested by funds: $581M → $384M (-$198M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$15.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.56M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$2.39M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.94M |
| 5 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$24.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$15.2M |
| 3 |
JG
Jefferies Group
New York
|
-$5.37M |
| 4 |
CCM
Cadian Capital Management
New York
|
-$3.15M |
| 5 |
BC
Broadfin Capital
New York
|
-$2.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICAS
101
Investors Capital Advisory Services
Lynnfield,
Massachusetts
| – | -$121K | -386 | Closed |
|
102
Neuberger Berman Group
New York
| – | -$118K | -375 | Closed |
|
|
MC
103
Menta Capital
San Francisco,
California
| – | -$109K | -346 | Closed |
|
|
PA
104
Perceptive Advisors
New York
| – | -$44K | -140 | Closed |
|
TXMD Hedge Fund Activity: Q2 2014 in Review
87 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2014, worth a combined $384M — down 34% from $581M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TXMD positions and 17 closed out — a net gain of 4 holders — while 32 added to existing stakes and 26 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $15.1M. The largest seller was RA Capital Management, cutting an estimated $24.6M.
- 87 institutional investors held TherapeuticsMD (TXMD) as of Q2 2014, up from 83 in Q1 2014.
- Funds reported $384M of TherapeuticsMD stock for Q2 2014, down 34% quarter-over-quarter.
- 21 funds opened new TherapeuticsMD positions in Q2 2014 and 17 closed out, a net change of +4 holders.
- The largest TherapeuticsMD buyer in Q2 2014 was Bank of New York Mellon, an estimated $15.1M added.
- The largest TherapeuticsMD seller in Q2 2014 was RA Capital Management, an estimated $24.6M sold.
Based on aggregated 13F filings for Q2 2014.